Postremission therapy in adults with acute myeloid leukemia

Seminars in Hematology

Volumn 38, Issue 3 SUPPL. 6, 2001, Pages 17-23

  Stone, Richard M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CYTARABINE; MYELOABLATIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER REGRESSION; CANCER SURVIVAL; CYTOGENETICS; HISTOCOMPATIBILITY; HUMAN; KARYOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0034888142     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2001.24264     Document Type: Review

References (43)

1. A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia
2. Acute myelogenous leukaemia: Maintenance chemotherapy after early consolidation treatment does not prolong survival
3. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia
4. Biochemical and cellular pharmacology of cytosine arabinoside
5. Treatment of acute myeloblastic leukemia in adults. The GOELAM experience
6. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial
7. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities
8. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: The BGMT 87 study
9. Varying intensity of postremission therapy in acute myeloid leukemia
10. Intensive postremission chemotherapy in adults with acute myeloid leukemia
11. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
12. Intensified post-remission chemotherapy for adults with acute myelogenous leukemia: An update of CALGB 8525
13. Risk factors for high-dose cytarabine neurotoxicity: An analysis of a Cancer and Leukemia Group B trial in patients with acute myeloid leukemia
14. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency
15. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
16. Acute leukemias with structurally altered core binding factor subunits (t(8;21), inv(16), t(12,22))
17. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
18. A comparison of sequential non-cross-resistant therapy or Ara-C consolidation following complete remission in adult patients < 60 years with acute myeloid leukemia: CALGB 9222
19. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide
20. Autologous stem cell transplantation in acute myelocytic leukemia
21. Autologous bone marrow transplantation for acute myelocytic leukemia in Europe. Further evidence of the role of marrow purging by mafosfamide
22. Marrow transplantation in patients with acute myeloid leukemia
23. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood
24. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial
25. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
26. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia
27. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
28. Autologous stem cell transplantation for acute myeloid leukemia in first remission
29. Oncogenic transcription factors in the human acute leukemias
30. All-trans-retinoic acid in acute promyelocytic leukemia
31. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis
32. Radioimmunotherapy of hematological cancer: Problems and progress
33. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
34. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia
35. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy
36. Interleukin 2 in the treatment of acute leukemia
37. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of Cancer and Leukemia Group B study 9420
38. Donor leukocyte infusions in 140 patients with relapsed malignancy after bone marrow transplantation
39. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
40. T cells, graft-versus-host disease and graft-versus-leukemia: Innovative approaches for blood and marrow transplantation
41. Interleukin-12 gene immunotherapy induces effective prophylactic and therapeutic immunity in murine acute myeloid leukemia
42. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
43. + acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells